Navigation Links
Cardiome meldet Veröffentlichung positiver Ergebnisse aus Vergleichsstudie von Vernakalant IV mit Propafenon und Flecainid
Date:9/24/2013

? Journal of Atrial Fibrillation. 2013;6(2). Online-Zugriff am 17. September 2013

Informationen zur Cardiome Pharma Corp.

Die Cardiome Pharma Corp. ist ein Biopharmaunternehmen, das sich der Entdeckung, Entwicklung und Vermarktung von neuen Therapien verschrieben hat, die der Gesundheit von Patienten aus aller Welt zugutekommen. Das einzige von Cardiome vermarktete Produkt BRINAVESS[TM] (Vernakalant IV) ist in Europa und anderen Gebieten zur raschen Konversion von jüngst ausgebrochenem Vorhofflimmern zum Sinusrhythmus bei Erwachsenen zugelassen.

Die Aktien von Cardiome sind am NASDAQ Capital Market (CRME) und an der Börse Toronto (COM) gelistet. Nähere Informationen erhalten Sie auf unserer Website http://www.cardiome.com.

Haftungsausschluss in Bezug auf vorausschauende Aussagen

Bestimmte Aussagen in dieser Pressemitteilung enthalten vorausschauende Aussagen im Sinne des Private Securities Litigation Reform Act von 1995 bzw. zukunftsgerichtete Informationen im Sinne gültiger kanadischer Wertpapiergesetze, die unter Umständen nicht auf historischen Tatsachen beruhen. Ohne jegliche Einschränkung zählen hierzu Aussagen, die die Begriffe "glauben", "können", "planen", "werden", "schätzen", "weiterhin", "antizipieren", "beabsichtigen, "erwarten" sowie ähnliche Formulierungen enthalten. Vorausschauende Aussagen können unter Umständen Bemerkungen bezüglich unserer Ziele und Prioritäten für den verbleibenden Teil des Jahres 2013 und darüber hinaus enthalten, sind aber nicht auf solche beschränkt. Zudem können sie sich auf Strategien und zukünftige Maßnahmen, Zielvorgaben, Erwartungen bezüglich unserer finanziellen Lage sowie auf die Ergebnisse und Prognosen unserer Geschäfts-, Forschungs- und Entwicklungsaktivitäten und unserer
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
2. Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... YORK, Jan. 15 - The Michael J. Fox,Foundation ... total funding for seven research studies aiming to ... drug makers, to,therapeutically target two genes -- LRRK2 ... only partially understood, role in Parkinson,s disease., ...
... Kan., Jan. 15 The Kansas Bioscience,Authority ... bring together,researchers nationwide to create products that ... diseases to disrupt the national economy or,to ... new Collaborative Biosecurity Research Initiative,(CBRI) are to ...
... Group plc (AIM:,PRG), the international pharmaceutical services ... Senior Director, Clinical Trial Management,specializing in oncology-related ... a leading role in the operations, strategic ... portfolio of oncology,business., Over the past ...
Cached Biology Technology:The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinson's Disease 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 2Collaborative Biosecurity Research Initiative Launched to Target Animal and Public Health Threats Nationally 3Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management 2
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... FL. Research to be presented at the upcoming ... Ingestive Behavior (SSIB), the foremost society for research into ... people can become dependent on highly palatable foods and ... the behaviors we observe in drug addicts and those ...
... can make a significant contribution to carbon storage and, ecologists ... and gardeners planted and maintained more trees. The study, published ... Applied Ecology , is the first to quantify how much ... Europe. Using satellite data and information gathered by visiting ...
... Toronto, ON - When it comes to how they ... from humans. Recent studies showed that even genetically ... a disease. This is because each twin has distinct personal ... the same is likely true for forest trees as well, ...
Cached Biology News:Evidence for 'food addiction' in humans 2Plants in cities are an underestimated carbon store 2New research shows forest trees remember their roots 2
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from ... repeat pipetting. It is the only ... most standard syringe tips, including BRAND ... Combi-Tips Plus, Fisherbrand Dispenser Tips,and VWRbrand ...
Biology Products: